Author

L. H. Yamashiro

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

X. Nguyenla· 3 shared C. Dugast-Darzacq· 2 shared E. Van Dis· 2 shared E. Wehri· 2 shared J. Schaletzky· 2 shared S. B. Biering· 2 shared S. Stanley· 2 shared A. M. Näär· 1 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 34 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

X. Nguyenla

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

MicrobiologybioRxivMay 17, 2021

An intranasal ASO therapeutic targeting SARS-CoV-2

C. Zhu, J. Y. Lee, J. Z. Woo…·A. M. Näär

This paper develops an intranasal ASO therapy targeting SARS-CoV-2 RNA that effectively prevents viral replication in multiple models and variants.

DOI 10.1038/s41467-022-32216-0

𝕏 PostBluesky

MicrobiologybioRxivDec 30, 2020

Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2

S. B. Biering, E. Van Dis, E. Wehri…·S. A. Stanley

This study screens FDA-approved compounds for antiviral activity against SARS-CoV-2 and identifies 13 effective compounds, including seven new candidates and one synergistic combination with remdesivir.

DOI 10.1021/acsinfecdis.1c00017

humanexperimental assay

𝕏 PostBluesky

MicrobiologybioRxivSep 18, 2020

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells

X. Nguyenla, E. Wehri, E. Van Dis…·J. Schaletzky

This study identifies 20 approved drugs that synergize with remdesivir to inhibit SARS-CoV-2 replication in human lung cells, with HCV NS5A inhibitors showing the strongest effects.

DOI 10.1038/s41598-022-21034-5

humanbulk RNA-seq

𝕏 PostBluesky

ImmunologybioRxivPreprintDec 12, 2019

STING controls Herpes Simplex Virus in vivo independent of type I interferon induction

L. H. Yamashiro, S. C. Wilson, H. M. Morrison…·R. Vance

This study shows that STING controls HSV-1 infection independently of type I interferon induction, through autophagy and other ancestral functions.

DOI 10.1101/2019.12.12.874792

mouseexperimental assay

𝕏 PostBluesky